Metsera (MTSR) Competitors $28.68 -0.57 (-1.95%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MTSR vs. RDY, VTRS, MRNA, ASND, QGEN, ROIV, RVMD, BPMC, BBIO, and ELANShould you be buying Metsera stock or one of its competitors? The main competitors of Metsera include Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Moderna (MRNA), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Metsera vs. Dr. Reddy's Laboratories Viatris Moderna Ascendis Pharma A/S Qiagen Roivant Sciences Revolution Medicines Blueprint Medicines BridgeBio Pharma Elanco Animal Health Metsera (NASDAQ:MTSR) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, community ranking, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Do institutionals and insiders hold more shares of MTSR or RDY? 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor MTSR or RDY? In the previous week, Dr. Reddy's Laboratories had 12 more articles in the media than Metsera. MarketBeat recorded 13 mentions for Dr. Reddy's Laboratories and 1 mentions for Metsera. Dr. Reddy's Laboratories' average media sentiment score of 1.61 beat Metsera's score of 0.73 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metsera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 13 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community believe in MTSR or RDY? Dr. Reddy's Laboratories received 318 more outperform votes than Metsera when rated by MarketBeat users. However, 100.00% of users gave Metsera an outperform vote while only 59.41% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformMetseraOutperform Votes4100.00% Underperform VotesNo VotesDr. Reddy's LaboratoriesOutperform Votes32259.41% Underperform Votes22040.59% Is MTSR or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 17.25% compared to Metsera's net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 17.87% beat Metsera's return on equity.Company Net Margins Return on Equity Return on Assets MetseraN/A N/A N/A Dr. Reddy's Laboratories 17.25%17.87%12.32% Which has preferable earnings & valuation, MTSR or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than Metsera. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetseraN/AN/AN/AN/AN/ADr. Reddy's Laboratories$325.54B0.04$668M$0.6621.87 Do analysts prefer MTSR or RDY? Metsera presently has a consensus target price of $47.00, suggesting a potential upside of 55.47%. Dr. Reddy's Laboratories has a consensus target price of $17.00, suggesting a potential upside of 17.78%. Given Metsera's stronger consensus rating and higher possible upside, research analysts clearly believe Metsera is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metsera 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryDr. Reddy's Laboratories beats Metsera on 9 of the 13 factors compared between the two stocks. Get Metsera News Delivered to You Automatically Sign up to receive the latest news and ratings for MTSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTSR vs. The Competition Export to ExcelMetricMetseraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.18B$6.54B$5.40B$8.49BDividend YieldN/A2.66%5.22%4.11%P/E RatioN/A9.1826.7119.93Price / SalesN/A256.43395.44119.84Price / CashN/A65.8538.2534.62Price / BookN/A6.536.854.59Net IncomeN/A$144.00M$3.23B$248.19M7 Day Performance23.44%5.01%5.35%2.21%1 Month Performance54.95%9.58%13.31%16.23%1 Year PerformanceN/A-0.94%17.58%8.00% Metsera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTSRMetseraN/A$28.68-1.9%$47.00+63.9%N/A$3.01BN/A0.0081RDYDr. Reddy's Laboratories2.3333 of 5 stars$14.44+0.3%$17.00+17.8%+5.3%$12.05B$325.54B22.9924,800Positive NewsGap UpVTRSViatris2.0946 of 5 stars$8.84+0.6%$10.50+18.8%-19.8%$10.38B$14.33B-11.9537,000Trending NewsMRNAModerna4.4646 of 5 stars$24.86+5.1%$53.95+117.0%-80.2%$9.61B$3.14B-2.683,900News CoverageGap UpASNDAscendis Pharma A/S3.508 of 5 stars$157.60+0.0%$216.07+37.1%+33.5%$9.61B$368.70M-22.20640QGENQiagen3.9935 of 5 stars$42.65+1.0%$48.42+13.5%-3.4%$9.48B$1.98B118.766,030Positive NewsROIVRoivant Sciences1.9729 of 5 stars$10.79+0.3%$17.50+62.2%-2.9%$7.70B$122.59M-71.93860Positive NewsRVMDRevolution Medicines4.366 of 5 stars$39.54+0.3%$67.08+69.7%+1.1%$7.37B$742,000.00-11.01250Positive NewsBPMCBlueprint Medicines1.7929 of 5 stars$101.69+2.2%$126.56+24.5%-1.2%$6.57B$562.12M-94.16640Positive NewsInsider TradeBBIOBridgeBio Pharma4.6002 of 5 stars$33.84+0.3%$57.09+68.7%+14.2%$6.43B$127.42M-11.87400Positive NewsInsider TradeELANElanco Animal Health3.2195 of 5 stars$12.940.0%$15.00+16.0%-23.1%$6.42B$4.43B32.349,800Analyst ForecastGap Up Related Companies and Tools Related Companies RDY Alternatives VTRS Alternatives MRNA Alternatives ASND Alternatives QGEN Alternatives ROIV Alternatives RVMD Alternatives BPMC Alternatives BBIO Alternatives ELAN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTSR) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MTSR Stock Free MTSR Stock Alerts